Corient IA LLC Makes New Investment in Takeda Pharmaceutical Co. $TAK

Key Points

• Corient IA LLC acquired 40,000 shares of Takeda Pharmaceutical Co., valued at approximately $595,000, marking a significant investment by the fund in the first quarter.
• Multiple hedge funds are increasing their stakes, with Fifth Third Bancorp growing holdings by 85.5% and others like Farther Finance Advisors LLC and Point72 Hong Kong Ltd also entering new positions.
• Takeda's stock performance features a current market value of $47.70 billion and reported a quarterly EPS of $0.52, beating analyst expectations of $0.47.

Corient IA LLC purchased a new stake in shares of Takeda Pharmaceutical Co. (NYSE:TAK - Free Report) during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 40,000 shares of the company's stock, valued at approximately $595,000.

Several other hedge funds have also modified their holdings of TAK. JPMorgan Chase & Co. grew its stake in shares of Takeda Pharmaceutical by 94.5% during the fourth quarter. JPMorgan Chase & Co. now owns 83,826 shares of the company's stock valued at $1,110,000 after purchasing an additional 40,721 shares during the last quarter. Franklin Resources Inc. boosted its stake in Takeda Pharmaceutical by 16.2% in the fourth quarter. Franklin Resources Inc. now owns 19,791 shares of the company's stock valued at $262,000 after acquiring an additional 2,763 shares during the last quarter. Russell Investments Group Ltd. boosted its stake in Takeda Pharmaceutical by 48.6% in the fourth quarter. Russell Investments Group Ltd. now owns 45,324 shares of the company's stock valued at $600,000 after acquiring an additional 14,831 shares during the last quarter. Bank of Montreal Can boosted its stake in Takeda Pharmaceutical by 8.9% in the fourth quarter. Bank of Montreal Can now owns 86,776 shares of the company's stock valued at $1,149,000 after acquiring an additional 7,124 shares during the last quarter. Finally, Raymond James Financial Inc. bought a new position in Takeda Pharmaceutical in the fourth quarter valued at approximately $1,447,000. 9.17% of the stock is owned by institutional investors.

Takeda Pharmaceutical Trading Up 1.8%

TAK stock traded up $0.2750 during midday trading on Wednesday, reaching $15.4750. The company's stock had a trading volume of 3,275,109 shares, compared to its average volume of 2,551,147. Takeda Pharmaceutical Co. has a 52 week low of $12.80 and a 52 week high of $15.56. The stock has a market cap of $49.24 billion, a PE ratio of 51.58 and a beta of 0.22. The company has a quick ratio of 0.59, a current ratio of 1.16 and a debt-to-equity ratio of 0.60. The business's 50-day simple moving average is $14.79 and its 200-day simple moving average is $14.64.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last announced its quarterly earnings data on Wednesday, July 30th. The company reported $0.52 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.47 by $0.05. Takeda Pharmaceutical had a net margin of 3.20% and a return on equity of 10.50%. The firm had revenue of $7.45 billion for the quarter, compared to analysts' expectations of $7.96 billion. Takeda Pharmaceutical has set its FY 2025 guidance at 3.360-3.360 EPS. As a group, sell-side analysts expect that Takeda Pharmaceutical Co. will post 1.64 EPS for the current year.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.